Urolithin A for Aging
Urolithin A is widely sold as an anti-aging supplement, but the best human evidence is weak and disputed: it shifts some mitochondrial and inflammation markers and may slightly improve muscle strength, yet it has not been shown to slow aging or improve overall physical function. Regulatory clearances (FDA, EFSA, TGA) cover food safety only, not any proven anti-aging benefit.
Why this grade7-layer evidence engine
The grade is Weak (Tier C), Disputed. The strongest source, a 2024 academic systematic review of five small RCTs in healthy adults (PMID 39002645, n=250), found a dose-dependent anti-inflammatory effect, upregulation of mitochondrial and autophagy genes, and small gains in muscle strength and endurance. Crucially, it found no effect on ATP production, mitochondrial biogenesis, cardiovascular outcomes, or overall physical function, and its authors concluded the evidence is insufficient to confirm meaningful geroprotective activity in humans.
Supportive reviews are weaker and conflicted. A 2023 scoping review (PMID 37637627) calls the data largely mechanistic and early-stage, a 2025 study (PMID 40944367) is preclinical (worms and cells, mechanism only), and the most positive muscle-aging review (PMID 37925671) is a low-quality narrative paper written by employees of the manufacturer (Amazentis/Mitopure) — a clear conflict of interest. Positive single-trial signals largely vanished once pooled.
Regulators and clinics do not endorse anti-aging use. FDA ('no questions', GRAS), EFSA (safe up to 500 mg/day), TGA and Health Canada clearances address food safety, not efficacy for aging. Major clinical bodies (NIH ODS, Mayo Clinic, Cleveland Clinic, Harvard) do not address it; a geriatrics-journal abstract (PMC6183836) only notes it is well tolerated in older adults. Safety clearance must not be read as proof it works.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.58
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — | B→C 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
- detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status